Skip to content
OpenCapital
Get started

Organon OGN Nexplanon/Implanon NXT — Revenue

Other product segments

Other
$87M+11.5%
Zetia
$87M+2.4%
Atozet
$85M+10.4%
Other Non-Opiod Pain, Bone and Dermatology
$68M0.0%
Hadlima
$67M+42.6%
Nasonex
$65M-9.7%
Follistim AQ
$61M-11.6%
Arcoxia
$59M-4.8%
Cozaar/Hyzaar
$57M+3.6%
Renflexis
$57M0.0%
Emgality
$54M+68.8%
Other Women's Health
$46M+7.0%
Singulair
$40M-45.9%
Diprospan
$35M+16.7%
Dulera
$35M-18.6%
Clarinex
$31M-8.8%
Propecia
$30M+15.4%
Fosamax
$29M-12.1%
Other Cardiovascular
$28M-6.7%
Ganirelix Acetate Injection
$26M-3.7%
Marvelon/Mercilon
$26M-33.3%
Proscar
$26M+8.3%
Vtama
$25M+4.2%
NuvaRing
$24M+9.1%
Other Biosimilars
$24M—
Vytorin
$21M-8.7%
Brenzys
$20M+42.9%
Other Respiratory
$12M-7.7%
Rosuzet
$6M+50.0%
Jada
$5M-66.7%
Ontruzant
$5M-72.2%

Similar metrics at other companies

Amgen logo
AMGNNplate — Total revenues
$412M+31.6%
Amneal Pharmaceuticals, Inc. logo
AMRXInjectable — Net revenue
$49.94M+43.5%
Johnson & Johnson logo
JNJINVEGASUSTENNAXEPLIONTRINZATREVICTA — Sales to customers (Note 9)
$1.04B+15.0%
Amneal Pharmaceuticals, Inc. logo
AMRXHormonal / allergy — Net revenue
$35.93M+5.1%
AbbVie logo
ABBVVenclexta — Net revenues
$770M+15.8%
Pfizer logo
PFEInlyta — Revenues:
$214M-2.3%

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%
Enterprise value$10.98B-26.4%
P/E6.6×+2.1×
P/S0.6×-0.8×

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%—
Debt / equity9.5×-7.0×
Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's nexplanon/implanon nxt — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's nexplanon/implanon NXT — revenue?
Organon (OGN) reported nexplanon/implanon NXT — revenue of $201M in Q1 2026.
How has Organon's nexplanon/implanon NXT — revenue changed year-over-year?
Organon's nexplanon/implanon NXT — revenue decreased by 19.0% year-over-year, from $248M to $201M.
What is the long-term trend for Organon's nexplanon/implanon NXT — revenue?
Over 4 years (2021 to 2025), Organon's nexplanon/implanon NXT — revenue has grown at a 4.6% compound annual growth rate (CAGR), from $768M to $921M.
What does nexplanon/implanon NXT — revenue mean?
This metric represents the total gross sales generated from the specific long-acting reversible contraceptive product line, net of returns, allowances, and rebates. It serves as a primary indicator of market demand, product adoption, and competitive positioning within the women's health therapeutic category. Tracking this revenue stream helps investors assess the commercial performance and growth trajectory of key pharmaceutical assets.